Human prolactin (hPRL) promotes the proliferation and differentiation of mammary epithelial cells during mammary gland development and has been linked to breast tumor development. The receptor for hPRL (hPRL-R) is elevated in a majority of human breast tumors, suggesting the overexpression of hPRL-R makes cancer cells highly sensitive to the mitogenic and anti-apoptotic activity of hPRL. These findings provide the rationale for the development of hPRL-R targeting breast cancer therapeutics. Previously, an hPRL-R antagonist, G129R, was developed that competitively binds to the hPRL-R resulting in growth inhibition and the induction of apoptosis in certain types of breast cancer cells. To further increase the potency of G129R, we fused G129R to a truncated form of Pseudomonas exotoxin A (PE 40 ) that lacks the cell recognition domain of the toxin but retains the domains necessary for PE 40 to translocate into the cytosol and inhibit protein synthesis. We postulated that the fusion of G129R with PE 40 -KDEL would (1) deliver the recombinant toxin to breast cancer cells where hPRL-R is overexpressed; (2) block hPRL signaling via its G129R moiety; and (3) inhibit protein synthesis via its PE 40 -KDEL moiety. We demonstrate that the fusion toxin can competitively bind to hPRL-Rs on T-47D human breast cancer cells and inhibit STAT5 phosphorylation induced by hPRL. In addition, we show that G129R-PE 40 -KDEL is selectively cytotoxic to breast cancer cell lines expressing the hPRL-R and that cell death is associated with the inhibition of protein synthesis and does not involve caspase mediated apoptosis.
Introduction
Human prolactin (hPRL) promotes the proliferation and differentiation of mammary epithelial cells during mammary gland development and is necessary for the stimulation of lactogenesis. The receptor for hPRL (hPRL-R) is up regulated in mammary tissue during development and studies have shown that a majority of human breast tumors have higher hPRL-R levels than surrounding normal mammary tissue [1] [2] [3] . It has also been shown that hPRL mRNA and protein are present in both normal and cancerous human mammary tissue [4, 5] and that it originates primarily from the mammary epithelium [3] . Based on these observations, it has been hypothesized: (1) that elevated hPRL-R levels in malignant breast tissue make these cells highly sensitive to the mitogenic and anti-apoptotic activity of hPRL; (2) that hPRL released from the epithelial cells acts locally via the hPRL-R in an autocrine/paracrine loop; and (3) that alterations in hPRL signaling may play a role in malignant transformation and/or tumor development.
Since both hPRL and hPRL-R are expressed widely in breast cancers, it was proposed that targeted inhibition of signaling via the hPRL-R would have potential as a therapy for breast cancers [6] . In vitro, anti-hPRL antibodies and anti-sense RNA directed against the hPRL gene have been used to successfully inhibit T-47Dco cell proliferation [7, 8] as have antibodies against hPRL-R in multiple breast cancer cell lines [9] . An antibody raised against the PRL-R has also been shown to reduce the incidence of carcinogen induced breast cancers in vivo in mice [10] . These findings validate hPRL/hPRL-R signaling as a target for the development of breast cancer therapeutics.
An hPRL-R antagonist, G129R, was developed by substituting a single glycine residue at position 129 of hPRL with a bulky arginine residue [11, 12] . This amino acid substitution disrupts the structural integrity of the lower affinity-binding site of hPRL so that it retains the ability to bind to the first receptor with high affinity but can no longer interact with a second receptor to initiate signal transduction [12, 13] . We demonstrated that G129R binds to the hPRL-R with similar affinity as hPRL and is able to competitively antagonize the effects of hPRL on hormone responsive human breast cancer cell lines [12] . We further demonstrated that the antagonist competitively blocks hPRL-induced Janus-associated kinase/signal transducers and activators of transcription (JAK/STAT) signaling and by doing so results in the up-regulation of a tumor suppressor (TGF-b ) and the down-regulation of a protooncogene (bcl-2); leading to the arrest of cell cycle progression and in some circumstances the induction of apoptosis [14] [15] [16] [17] . Since the blocking of hPRL signaling by G129R appears to be more cytostatic than cytotoxic to breast cancer cells in vitro and in vivo using mouse xenografts [18] , we proposed to enhance the cytotoxicity of G129R by fusing it to a toxin that potently inhibits protein synthesis.
Pseudomonas exotoxin A (PE) is a bacterial toxin with three structurally and functionally different domains [19, 20] . Domain I is responsible for cell recognition, domain II for translocation, and domain III for inhibition of protein synthesis. PE binds to the membrane-associated heavy chain of a 2 -macroglobulin receptor and undergoes receptor-mediated endocytosis [21] [22] [23] . Within the endosome PE is acidified and processed [24] [25] [26] [27] ; the low pH induces conformational changes in PE necessary for translocation [28] and for processing by furan [29, 30] , which cleaves PE between arginine 279 and glycine 280 [31] . The mechanism by which the 37 kDa C-terminal fragment of PE translocates to the cytosol remains unclear; however, both the amino-terminal [32, 33] and carboxy-terminal regions of PE 37 are necessary for translocation. The carboxy-terminal five amino acids, REDLK, resemble an endoplasmic reticulum (ER) retention signal [34] and are necessary for cytotoxicity [32] . After removal of the C-terminal lysine, this carboxyl-terminal fragment is thought to exploit the KDEL receptor retrieval system by binding to KDEL receptors present in the Golgi, which retrograde transport the toxin to the lumen of the ER [35, 36] . In the ER, PE may be reduced, unfolded and reverse translocated across the membrane into the cytosol where it can inactivate elongation factor 2 (EF-2), thereby inhibiting protein synthesis and ultimately causing cell death.
Here we describe the development of a fusion toxin intended to specifically target and kill hPRL-R-positive breast cancers using G129R and a recombinant form of Pseudomonas exotoxin A that lacks the cell recognition domain. Our data demonstrates that G129R-PE 40 -KDEL drastically increases the potency of G129R even though it has a lower affinity for the hPRL-R when fused with PE 40 -KDEL. We show that G129R-PE 40 -KDEL has the attributes of a dual function protein; it retains the ability to antagonize the hPRL-R by partially inhibiting hPRL-induced STAT5 phosphorylation and it drastically reduces the viability of hPRL-R positive human breast cancer cells by inhibiting protein synthesis.
Materials and methods

Cell lines and reagents
The human breast cancer cell lines T-47D, MCF-7, BT-474, BT-483, MDA-MB-134, MDA-MB-453, MDA-MB-231 and the murine breast cancer cell line 4T1 were purchased from the American Type Culture Collection (Manassas, VA) and were maintained in medium containing 10 lg/ml gentamicin at 37°C with humidity and 5% CO 2 unless otherwise mentioned. All media and supplements were purchased from Invitrogen (Carlsbad, CA) unless otherwise mentioned. T-47D and MCF-7 cells were maintained in RPMI Medium 1640 supplemented with 10% fetal bovine serum (FBS). BT-474 cells were maintained in RPMI Medium 1640 supplemented with 10% FBS, 1 mM sodium pyruvate, and 10 lg/ml insulin (Sigma, St. Louis, MO). BT-483 cells were maintained in RPMI Medium 1640 supplemented with 20% FBS, 2.5 mg/ml glucose (Sigma), 10 mM HEPES, 1 mM sodium pyruvate, and 10 lg/ml insulin. MDA-MB-134 cells were maintained in Leibovitz's L-15 Medium supplemented with 20% FBS without CO 2 . MDA-MB-453 and MDA-MB-231 cells were maintained in Leibovitz's L-15 Medium supplemented with 10% FBS without CO 2 . 4T1 cells were maintained in RPMI Medium 1640 supplemented with 10% FBS, 2.5 mg/ml glucose (Sigma), 10 mM HEPES, and 36.4 ml of 7.5% (w/v) sodium bicarbonate per liter of medium.
Pseudomonas exotoxin A was purchased from List Biological Laboratories (Campbell, CA). PE 40 , which retains the enzymatic activity of the toxin but has low cytotoxicity due to the lack of the cell recognition domain Ia [37] , was prepared and purified as described previously from the periplasmic fraction [38] . Recombinant hPRL and G129R were prepared in house as previously described [18] . Cbz-Val-Ala-Asp-(Ome)-fluoromethyl ketone (zVAD-fmk) was purchased from Enzyme Systems Products (Livermore, CA) and dissolved in DMSO (Fisher Scientific, Pittsburgh, PA) to a final concentration of 50 mM, aliquoted, and stored at )20°C. Working solutions were made in culture medium immediately before use.
Construction of PRL-PE 40 -KDEL and G129R-PE 40 -KDEL expression vectors
Previously, hPRL and G129R were cloned by inserting their cDNAs between the NdeI and XhoI sites of the expression vector pET22b obtained from Novagen (Madison, WI). Plasmid JH8, which encodes a recombinant form of Pseudomonas exotoxin A (PE 40 ), was obtained from the American Type Culture Collection (Manassas, VA). All oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA), all restriction and modifying enzymes were purchased from New England BioLabs (Beverly, MA), and all PCR reactions were performed using the Advantage-HFÔ Kit (BD Biosciences, Palo Alto, CA). Internal BamHI and XhoI sites were removed from the DNA encoding PE 40 using the QuickChange Ò XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The carboxy-terminal codons of hPRL, G129R, and PE 40 were modified and restriction sites were added by PCR using oligonucleotides; the stop codons of hPRL and G129R were replaced with codons encoding GGGGS and the codons of PE 40 encoding REDLK were replaced with codons encoding KDEL since it has been shown to significantly increase the cytotoxicity of PE and its derivatives [37] . The PCR products were ligated with pCR2.1 T/A cloning vector and transformed into E. coli TOP10 cells obtained from Invitrogen. Positive clones were identified by plating the cells on Luria-Bertani (LB) agar plates containing 100 lg/ml ampicillin and 80 lg/ ml 5-bromo-4-chloro-3-indolyl-bD-galactoside. The plasmids were isolated using the QIAprepÒ Spin Miniprep Kit (Qiagen, Valencia, CA) and the NdeI-PRL-G 4 S-BamHI, NdeI-G129R-G 4 S-BamHI, and BamHI-PE 40 -KDEL-XhoI DNA fragments were isolated by restriction digestion, separated by electrophoresis, purified from the agarose gel using the QIAquickÒ Gel Extraction Kit (Qiagen), and ligated with NdeI and XhoI cut pET22b to create pET22b-PRL-PE 40 -KDEL and pET22b-G129R-PE 40 -KDEL. Various oligonucleotides linkers were inserted at the BamHI site located between G129R and PE 40 -KDEL to increase the distance between the two moieties.
Production and purification of fusion toxins
Chemically competent E. coli BL21 (DE3) Star cells (Invitrogen) were transformed with pET22b-PRL-PE 40 -KDEL or pET22b-G129R-PE 40 -KDEL and propagated overnight at 37°C with agitation in LB broth containing 100 lg/ml ampicillin. The next morning 160 ml of each of the starter cultures was used to inoculate 4 l of LB broth and the cultures were grown to an O.D. 600 of 0.9 before induction of protein production with 1 mM isopropyl b-thiogalactoside (Alexis Biochemicals, San Diego, CA). After 5 h of induction the cells were harvested by centrifugation at 5000 · g for 5 min and resuspended in Solution 1 (0.2 M NaPO 4 ; 10 mM EDTA, pH 8.0; 0.5% Triton X-100; pH adjusted to 8.0) to which 0.1 mg/ml lysozyme was added. The cells were incubated at room temperature for 1 h to weaken the cell membranes before the cells were sheared on ice with five 1-min ultrasonic pulses (30% duty at setting 7) using a 550 Sonic Dismembrator (Fisher Scientific). The insoluble fraction containing the inclusion bodies was recovered by centrifugation at 12,000 · g for 30 min at 4°C and resuspended in Solution 2 (0.2 M NaPO 4 ; 10 mM EDTA, pH 8; 0.5% Triton X-100; 1 M urea; pH adjusted to 7.0). The inclusion bodies were collected by centrifugation at 12,000 · g for 30 min at 4°C and were solubilized and denatured in Solution 3 (0.2 M NaPO 4 ; 8 M urea; 1% v/v b-mercaptoethanol; pH adjusted to 8.0). The proteins were refolded by dialysis against baths of 20 mM Tris-HCl, pH 8.0 containing decreasing amounts of urea (4 M urea, 2 M urea, 0 M urea, 0 M urea). The refolded fusion toxins were filtered through 0.45 lm filters and purified by anionexchange chromatography using a 5 ml HiTrap Q Sepharose XL column (Amersham Biosciences, Piscataway, NJ) on an Ä KTA fast protein liquid chromatography system (Amersham Biosciences). The purified fusion toxins were separated by reducing SDS-PAGE along with BSA standards (Pierce, Rockford, IL) and stained with SYPRO Ò Orange (Molecular Probes, Eugene, OR) to determine the concentration and purity of the fusion toxins. The identity of the fusion toxins were confirmed by immunoblotting.
Immunoblot analysis
PE, G129R, and G129R-PE 40 
Radio-receptor binding assay
One million cells per well of T-47D human breast cancer cells were seeded in six-well tissue culture plates and grown to confluency. Cells were starved in serum-free RPMI Medium 1640 for 1 h, and incubated for 2 h at room temperature in serum-free medium containing 5 · 10 4 cpm of 125 I-labeled hPRL (specific activity, 40 lCI/lg; NEN Perkin-Elmer, Boston, MA) with or without various concentrations of hPRL, G129R, or G129R-PE 40 -KDEL. Cells were washed three times with serum-free RPMI Medium 1640 and were lysed in 0.5 ml of 0.1 N NaOH/1% SDS. Bound radioactivity was determined using a Beckman LS6500 Liquid Scintillation Counter calibrated to detect 125 I using a wide spectrometer window. The percentage of specific binding was calculated and compared among the samples.
STAT5 phosphorylation assay
T-47D cells were grown to 90% confluency in six-well plates in RPMI Medium 1640 supplemented with 10% (v/v) charcoal-stripped fetal bovine serum (CSS; HyClone, Logan, UT) and 10 lg/ml gentamycin. The cells were depleted for 1 h in RPMI Medium 1640 supplemented with 0.5% CSS and then treated for 20 min with various concentrations and combinations of hPRL, G129R, PRL-PE 40 -KDEL, and G129R-PE 40 -KDEL. The cells were washed with ice cold phosphate buffered saline (PBS) and lysed in 200 ll of Lysis Buffer (20 mM Tris-HCl, pH 7.4; 1% Igepal CA630; 6 mM deoxycholic acid; 150 mM NaCl; 1 mM EDTA, pH 8.0) containing protease inhibitors (1 lg/ml aprotinin; 1 lg/ml leupeptin; 170 lg/ml PMSF; 180 lg/ml sodium orthovanadate). The lysates were agitated for 10 min on an orbital shaker, transferred to 1.5 ml tubes, passed six times through 21-gauge needles, and incubated on ice for 20 min. The lysates were clarified by centrifugation for 10 min at 12,000 · g at 4°C and 30 ll of the supernatants were used for immunoblot analysis as described previously using 4-15% polyacrylamide gels. Blots were performed with 1.5 lg/ml mouse anti-phosphate STAT5A/B antibody (Upstate, Lake Placid, NY) and a 1:2000 dilution of goat anti-mouse-HRP conjugate (Bio-Rad). The membranes were re-probed with 3 lg/ml rabbit anti-STAT5 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and a 1:2000 dilution of goat ant-rabbit HRP conjugate (Bio-Rad).
Protein synthesis inhibition assay
Approximately 1 · 10 5 cells were seeded in each well of a 24-well plate in a final volume of 0.5 ml of appropriate growth medium and the cells were incubated overnight. The medium was replaced with 0.5 ml of appropriate treatments and incubated for 44 h after which each well was supplemented with 1 lCi of 3 H-leucine (Amersham Biosciences) in 100 ll of medium and incubated an additional 4 h. The monolayers were washed with 1 ml PBS and the protein was precipitated with 0.5 ml of 26% trichloroacetic acid (TCA) overnight at )20°C. The monolayers were solubilized with 0.5 ml of 0.2 nM NaOH and loaded onto GF/C glass fiber filters (Whatman, Clifton, NJ) pre-rinsed with 1 ml of 10% TCA. The filters were washed twice with 1 ml of 10% TCA and once with 3 ml of 95% ethanol and dried by vacuum. The dried filters were placed in scintillation vials and aqueous scintillation cocktail was added before counting with a liquid scintillation counter. The amount of 3 H-leucine incorporated into precipitable protein was determined and expressed as a percent of control.
Cell proliferation assay
The various cell lines to be assayed were seeded in 96-well culture plates at a density of 5000 cells per well in 200 ll of appropriate culture medium and grown as recommended. After incubation for 24 h, the medium was discarded and replaced with 200 ll of medium containing various concentrations of PE, G129R, or G129R-PE 40 -KDEL and the cells were incubated for an additional 48 h. The culture medium was discarded and replaced with 100 ll of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/ phenazine methosulfate (MTS/PMS) solution diluted in PBS at a 1:6 ratio (CellTiter 96 AQueous non-radioactive cell proliferation kit; Promega, Madison, WI). The relative viability of the cells was determined by colorimetric measurement of the reduction of MTS by the living cells using a Benchmark microplate reader (Bio-Rad) measuring absorbance at 490 nM. All assays were performed in quadruplicate and the relative cell viability was calculated as a percentage of control treatments.
Poly-(ADP-ribose)-polymerase (PARP) cleavage assay
Approximately 3 · 10 5 MCF-7 cells were resuspended in 5 ml of RPMI Medium 1640 supplemented with 10% CSS and seeded into T-25 flasks and allowed to grow 24 h. For experiments that included zVAD-fmk, 50 lM of the peptide was added 1 h prior to treatment with 1 lg/ml of PE, hPRL, G129R, or G129R-PE 40 -KDEL. After 24 h treatment, the medium and cells were collected and transferred to 5 ml Falcon tubes and centrifuged at 5000 · g. The pellets were washed once with ice-cold PBS and resuspended in 100 ll of Lysis Buffer with inhibitors and lysed for 30 min at 4°C. The lysates were clarified by centrifugation for 10 min at 12,000 · g at 4°C and the protein content of the lysates were assayed using the Coomassie Plus Protein Assay Reagent (Pierce). Thirty micrograms of the lysates were resolved on a 10% gel by reducing SDS-PAGE and were fsimmunoblotted as previously described using a blocking solution containing 10% milk. A 1:2000 dilution of rabbit anti-PARP (Roche) and 1:2000 dilution of goat anti-rabbit HRP conjugate (Bio-Rad) were used.
Results
Construction, expression, and purification of PRL-PE 40 -KDEL and G129R-PE 40 -KDEL To target the PE 40 toxin to the hPRL-R, we fused cDNA encoding hPRL or G129R to the N-terminus of DNA encoding PE 40 and replaced the DNA sequence encoding the native ER retention sequence (REDLK) of the toxin with a sequence encoding KDEL to increase its cytotoxicity (Figure 1) . Linkers of increasing length were inserted between hPRL or G129R and PE 40 -KDEL since the fusion toxins had little cytotoxicity with the Gly-Gly-Gly-Gly-Ser (G 4 S) linker. For all studies we used the fusion toxins containing the Gly-Gly-Gly-GlySer-Thr-Leu-Arg-Asp-Leu-Phe-Asp-Arg-Ala-Val-ValLeu-Ser-His-Tyr-Ile-His-Asn-Leu-Ser-Ser-Glu-Met-PheSer-Glu-Gly-Ser (helix1) linker since they showed greater potency. PRL-PE 40 -KDEL and G129R-PE 40 -KDEL were produced in E. coli and found to accumulate in the insoluble fraction as inclusion bodies. The inclusion bodies were isolated and denatured and the fusion toxins were refolded and purified by anion-exchange chromatography to yield preparations of greater than 90% purity. Purified G129R-PE 40 -KDEL was analyzed by reducing SDS-PAGE and was found to have a size corresponding to the predicted molecular mass of 66 kDa (Figure 2a) . Immunoblots with antibodies that detect the G129R and PE 40 -KDEL moieties confirmed the identity of purified protein to be G129R-PE 40 -KDEL (Figure 2b,c) .
G129R-PE 40 -KDEL binds to T-47D human breast cancer cells expressing hPRL-R
The ability of G129R and G129R-PE 40 -KDEL to specifically bind to hPRL-Rs expressed on the surface of T-47D human breast cancer cells was demonstrated using a radio-receptor binding assay. Figure 3 shows that increasing doses of hPRL, G129R, or G129R-PE 40 -KDEL were able to competitively reduce the binding of 125 I-hPRL to hPRL-Rs. This confirmed that G129R-PE 40 -KDEL retains the ability to bind to hPRL-Rs; however, the higher percent specific binding of 125 IhPRL suggests that G129R-PE 40 -KDEL has a reduced affinity for hPRL-Rs in comparison to hPRL and G129R. The EC 50 s for hPRL, G129R and G129R-PE 40 -KDEL were determined to be 2.7, 6.3, and 76.5 nM, respectively.
PRL-PE 40 -KDEL activates STAT5 and G129R-PE 40 -KDEL inhibits STAT5 phosphorylation in T-47D human breast cancer cells
Human PRL induces hPRL-R dimerization and leads to the phosphorylation of STAT5 via receptor associated JAK2. The PRL-PE 40 -KDEL fusion toxin retained the ability of the hPRL moiety to bind to hPRL-Rs on T-47D breast cancer cells and activate STAT5 phosphorylation (Figure 4) , albeit with only a fraction (1/10th) of the activity of hPRL. The ability of this fusion toxin to activate STAT5 suggested that G129R-PE 40 -KDEL should be able to bind to and antagonize the hPRL-R. Like G129R, G129R-PE 40 -KDEL did not activate STAT5 (Figure 5a ) and was able to compete with hPRL for occupancy of the hPRL-R as shown by its ability to partially block STAT5 phosphorylation (Figure 5b ). G129R-PE 40 -KDEL was unable to completely block the action of hPRL at a ratio of 1:100 and had antagonistic activity less than 1/10th that of G129R, which corresponds with the reduced activity observed for PRL-PE 40 -KDEL. These findings suggested the fusion toxins were still capable of binding to hPRL-R but with a reduced affinity. Figure 1 . Schematic representation of plasmid used to produce G129R-PE 40 -KDEL in E. coli. The cDNA encoding G129R was fused to the DNA encoding an enzymatically active form of PE (PE 40 -KDEL) with a BamHI site separating the two. In an effort to increase the activity of the fusion toxin, linkers of increasing length were inserted at the BamHI site between G129R and PE 40 -KDEL to decrease steric hindrance caused by their close proximity. The diagram above shows the amino acids encoded by the linkers inserted between G129R and PE 40 -KDEL. The fusion toxin used for all studies is shown underlined. The selection was based on its superior potency at inhibiting protein synthesis. The PE 40 -KDEL moiety of G129R-PE 40 -KDEL retains the ability to cleave PARP in MCF-7 cells
Having confirmed that the G129R moiety retains its ability to bind and block receptor activation, we wanted to determine if the PE 40 -KDEL moiety retained its activity. Previously, it has been shown that treatment of MCF-7 cells with PE results in the activation of caspases that cleave PARP into 89 and 24 kDa fragments [39] . Figure 6a shows that PE cleaved this DNA repair enzyme and that this cleavage was inhibited by treating the cells with the broad spectrum caspase inhibitor, zVAD-fmk. Neither hPRL nor G129R caused cleavage of PARP, confirming that the ability of G129R-PE 40 -KDEL to cleave PARP is due the PE 40 -KDEL moiety of the fusion toxin (Figure 6a) .
A cell proliferation assay was used to examine the cytotoxic effects of PE and G129R-PE 40 -KDEL on MCF-7 cells in the presence or absence of zVAD-fmk. Both PE and G129R-PE 40 -KDEL were found to have cytotoxic effects, confirming that at least a portion of the fusion toxin was taken up and processed correctly by MCF-7 cells (Figure 6b) . Interestingly, pretreatment with zVAD-fmk had little effect on the viability of the cells, suggesting that caspase mediated apoptosis plays no role in cell death associated with protein synthesis inhibition (Figure 6b ).
G129R-PE 40 -KDEL inhibits protein synthesis and decreases the viability of multiple human breast cancer cell lines expressing hPRL-R
Human breast cancer cell lines expressing various levels of hPRL-R were treated for 48 h with increasing doses of G129R-PE 40 KDEL and the inhibition of protein synthesis (Figure 7a ) and its effect on the relative viability of the cells (Figure 7b ) was determined by measuring the incorporation of 3 H-leucine into precipitable protein and by colorimetrically measuring the reduction of MTS by living cells, respectively. Cells expressing hPRL-Rs were markedly more sensitive to G129R-PE 40 -KDEL than cell lines such as MDA-MB231 and MDA-MB453 which lack or have few hPRL-Rs (Figure 7a,b) .
The inhibitory effect of G129R-PE 40 -KDEL is mediated via the G129R moiety and is due to the inhibition of protein synthesis by the PE 40 -KDEL moiety Previously, we have shown that G129R can inhibit the proliferation of breast cancer cells. At the concentrations used, G129R appeared to be cytostatic and did not decrease the viability of T-47D, MCF-7, or BT-474 breast cancer cells which have elevated levels of the hPRL-R (Figure 8) . Even with the greater than ten fold reduced receptor binding affinity and reduced antagonistic activity as indicated by STAT5 phosphorylation, G129R-PE 40 -KDEL was extremely cytotoxic in comparison to G129R. Fusion of G129R with PE 40 -KDEL drastically decreased the relative number of viable cells at concentrations well below those observed for G129R, suggesting that the increased cytotoxicity was due to the PE 40 -KDEL moiety of the fusion toxin.
To confirm that the killing observed with G129R-PE 40 -KDEL was not due to non-specific binding and to confirm that it was due to the inhibition of protein synthesis by the PE 40 -KDEL moiety, we measured the incorporation of 3 H-leucine into precipitable protein and the relative cell viability in response to G129R-PE 40 -KDEL in the absence or presence of competitors (Figures 9a,b) . Treatment of T-47D cells with increasing doses of G129R-PE 40 ing that the PE 40 -KDEL moiety was responsible for the inhibition of protein synthesis. Treatment of T-47D cells with increasing doses of G129R-PE 40 -KDEL also decreased the relative number of viable cells (Figure 9b ). Co-treatment of the cells with G129R-PE 40 -KDEL and G129R or hPRL revealed that the relative number of viable cells was increased by G129R and hPRL. This confirmed that the inhibition of protein synthesis was mediated through the hPRL-R and that the decreased viability was due to the PE 40 -KDEL moiety. We also examined the non-specific effects of G129R-PE 40 -KDEL in mouse 4T1 cells which are extremely sensitive to PE and the non-specific effects of PE 40 ; G129R-PE 40 -KDEL was found to have lower cytotoxicity than PE 40 by itself, suggesting that the fusion toxin has lower nonspecific cytotoxicity than PE 40 alone (Figure 10 ).
Discussion
Most growth factors and hormones are taken up by receptor-mediated endocytosis, a broadly named process that can involve a variety of different internalization pathways. For this reason, the ligand chosen for making a fusion toxin is not only important for determining its host-range, but also the ability of the toxin to be properly internalized and processed. Numerous fusion toxins have been constructed by gene fusion or conjugation of PE 40 with cytokines, growth factors, hormones, or antibodies. Most of these fusion toxins have proven to be cytotoxic to the targeted cells in the picomolar range. Based on the potency of PE based fusion toxins we wanted to examine the potential of a fusion toxin that targets the hPRL-R. Studies have shown that a majority of breast carcinomas express higher levels of hPRL-R than normal mammary tissue [1] [2] [3] and that their expression patterns differ markedly [40] . These observations suggest a relationship between hPRL-R overexpression and the pathology of breast carcinomas and were our justification for making G129R-PE 40 -KDEL.
Previous studies have reported the mechanism by which hPRL and G129R bind to the hPRL-R and . PARP cleavage and the effect of zVAD-fmk on the viability of MCF-7 breast cancer cells. Cells were treated for 24 h with 1 lg/ml of PE, PRL, G129R, or G129R-PE 40 -KDEL in the absence or presence of a broad spectrum caspase inhibitor, zVAD-fmk (a, b). The cell lysate was separated by reducing SDS-PAGE, and immunoblotted with anti-PARP antibody. The caspase mediated cleavage of PARP is indicated by the presence of a 24 kDa PARP fragment as shown by the arrow (a). The role of activated caspases in cytotoxicity caused by PE or G129R-PE 40 -KDEL was examined by measuring the reduction of MTS by living cells in the absence or presence of zVAD-fmk (b). Data presented is representative of the mean ± SD from assays performed in quadruplicate on two separate occasions. activate or inhibit signal transduction, respectively [11] [12] [13] . We have constructed G129R-interleukin 2 and G129R-endostatin fusion proteins and showed that their G129R moieties retain the ability to bind to the hPRL-R and competitively block hPRL-induced signal transduction [41, 42] . In these studies we also demonstrated that the interleukin 2 and endostatin portions of the fusion proteins retain their ability to bind to and activate receptors on T-cells and endothelial cells, respectively. The intracellular fate of these fusion proteins remains unknown and is inconsequential since their functions are believed to be served solely on the surface of the cells. Unlike G129R-interleukin 2 and G129R-endostatin, the fusion of G129R to PE 40 -KDEL would require hPRL-R mediated internalization and processing of the toxin to enter the cytoplasm and inhibit protein synthesis.
Little is known of the intracellular fate of hPRL and even less is known of the fate of G129R. In rat liver cells, it has been demonstrated that PRL undergoes receptor mediated endocytosis and accumulates intact in the Golgi region [43, 44] before degradation occurs [45] . In lactating rat mammary epithelial cells, PRL has been shown to avoid degradation in lysosomes by undergoing transcytosis; possibly via the fusion of the vesicles in the Golgi region with secretory vacuoles [46] . In addition to remaining in endosomes or undergoing degradation, PRL has also been shown to undergo nuclear retrotranslocation in rat Nb2 lymphoma cells [47] [48] [49] . This nuclear PRL has been shown to have nuclear actions [50, 51] and can modulate transcriptional events in part by interacting with chaperones such as cyclophilin B [52, 53] . In rat pituitary mammotrophs PRL was observed in all of these locations except lysosomes [54] . The presence of PRL in the Golgi apparatus, secretory vesicles, and the nucleus suggest multiple intracellular fates for PRL in addition to endosome/lysosomes, the organelle PE exploits to gain access to the cytoplasm.
In this study we demonstrate that G129R-PE 40 -KDEL is able to inhibit protein synthesis and cell proliferation in multiple breast cancer cell lines that express the hPRL-R (Figure 7 ). We did not anticipate that the inhibitory concentrations for G129R-PE 40 -KDEL would be in the nanomolar range rather than the picomolar range (Table 1) . To further examine this, we utilized T-47D breast cancer cells since they are hPRL responsive and express relatively high levels of hPRL-R [55] . We demonstrate that the inhibitory effects of G129R-PE 40 -KDEL can be reduced drastically by [Ligand] nM Relative Cell Viability (% of Control) PE PE40 G129R-PE40-KDEL G129R Figure 10 . Cytotoxicity assay using 4T1 mouse breast cancer cells. The consequence of fusing G129R to PE 40 -KDEL was examined to determine the effect on non-specific cytotoxicity. Cells were treated with PE, PE 40 , G129R-PE 40 -KDEL, or G129R and the relative number of viable cells was examined after 48 h by measuring the reduction of MTS. Data points presented are representative of the mean ± SD from assays performed in quadruplicate on two separate occasions. treatment with excess amounts of G129R or antibody against PE (Figure 9 ), suggesting that the cytotoxic effects of the fusion toxin rely heavily on cell binding and are mediated via the toxin moiety. We also examined the ability of G129R-PE 40 -KDEL to compete with 125 I-labeled hPRL for binding to T-47D cells and confirmed that G129R-PE 40 -KDEL is able to bind to the hPRL-R with an approximately 28-fold lower affinity than hPRL and approximately 11-fold lower affinity than G129R (Figure 3) .
The lower receptor binding affinity of G129R-PE 40 -KDEL may be due its size and a conformational change in the G129R moiety which make it less accessible to hPRL-R than G129R. The lower binding affinity of G129R-PE 40 -KDEL provides a logical explanation for its poor inhibitory effects on STAT5 activation by hPRL (Figure 5b ). The reduced affinity of G129R-PE 40 -KDEL for the hPRL-R may also account for the necessity to use nanomolar concentrations to inhibit protein synthesis and cause cell death. To ensure that the cytotoxicity observed in the nanomolar range was not due to non-specific binding, we examined the effects on mouse 4T1 cells which are extremely sensitive to the specific and non-specific effects of PE and PE 40 , respectively. We observed that fusion of G129R to PE 40 -KDEL actually reduced the non-specific side effects associated with PE 40 (Figure 10 ), suggesting that G129R-PE 40 -KDEL may actually decrease the non-specific cytotoxicity associated with the PE 40 moiety. To further ensure that the cytotoxicity observed was due to specific binding, we examined the effects on cell lines that express the hPRL-R. The concentrations of G129R-PE 40 -KDEL necessary to reduce the relative number of viable cells were orders of magnitude lower than the concentrations of G129R needed to show any affect ( Figure 8) ; similarly, treatment of the breast cancer cell lines with PE 40 alone resulted in little or no killing of the cells (data not shown). This suggests that the cytotoxic effects observed are mediated via the hPRL-R and only occur if G129R is fused with PE 40 -KDEL.
We evaluated the relationship between sensitivity to G129R-PE 40 -KDEL and hPRL-R mRNA expression level based on two studies that quantified the expression of the long isoform of hPRL-R mRNA in breast cancer cell lines using northern blot analysis [56] and real-time PCR [57] . Both studies identified T-47D, MDA-MB-134, MDA-MB-483, and BT-474 cells as having high hPRL-R levels; MCF-7 cells as having moderate levels; and MDA-MB-453 and MDA-MB-231 cells as having little or no expression. All of the cell lines reported to express high levels of hPRL-R were more sensitive than the cell lines reported to have few or no hPRL-R (Figure 7) . We also noticed that MCF-7 cells, reported to have modest hPRL-R levels, were more sensitive than all of the cell lines with high hPRL-R expression levels ( Figure 7) . The most obvious reason for the discrepancy would be that the mRNA levels do not necessarily correlate with actual hPRL-R levels; however, this would not explain why T-47D cells are not the most sensitive to G129R-PE 40 -KDEL since studies have shown they have the highest hPRL-R binding activity [55, 56] . Differences in the rate at which the PE 40 moiety is processed and translocated may affect the sensitivity of the cells. As controls for all of the cell proliferation assays, we examined the sensitivity of the cell lines to PE. All of the cell lines showed various degrees of sensitivity to PE, with MCF-7 cells being the most sensitive. This suggests processing of PE is the rate limiting step in intoxification and that sensitivity may not necessarily reflect hPRL-R expression levels.
Another explanation for the lack of a clear correlation between long isoform of hPRL-R mRNA expression level and sensitivity to G129R-PE 40 -KDEL may be explained by the complexity of hPRL-R expression. Multiple promoters [58] and multiple hPRL-R isoforms have been identified that arise from alternative splicing [59] . In addition to the long isoform of hPRL-R which activates all known hPRL signaling pathways, isoforms displaying differences in the extracellular or cytoplasmic domains have been identified that may have roles in the development and function of normal mammary tissue and breast carcinomas. A transcript that would result in a soluble form of hPRL-R has been found to be lower in breast carcinomas than in normal mammary tissue and may modulate the expression of the long isoform of hPRL-R [60] . An isoform of hPRL-R with an extracellular truncation has also been identified in normal and malignant breast tissue that has reduced binding affinity for hPRL [ 61] . Isoforms of hPRL-R with truncations in the cytoplasmic domain have also been identified that may affect intracellular signaling and the internalization rates. An intermediate isoform was identified in human breast cancer biopsies [62] that lacks STAT5 motifs and has diminished ability to activate Fyn [63] and two short isoforms have been identified that are incapable of activating Jak2/Stat5 signaling [64] . These short isoforms are expressed widely in human tissues and may modulate hPRL signaling through the long isoform by acting in a dominant negative manner [64, 65] . Recently, it has been observed that the ratio of short forms to long forms appears to be lower in breast carcinomas and breast cancer cell lines than in normal samples [66] . The short forms of the rodent and bovine PRL-R have been shown to have a slower internalization rate than the long isoform [67] . The presence of multiple hPRL-R isoforms with variations in expression level; the potential of these hPRL-Rs to form homo-and hetero-dimers with differences in binding affinity and internalization rates; and the lack of data concerning the trafficking and degradation of these various hPRL-R isoforms make it difficult to predict the potential effectiveness of G129R-PE 40 -KDEL based solely on hPRL-R mRNA expression levels. Studies regarding the status of hPRL-R in human breast cancer patients are limited in contrast to the estrogen receptor status. From the relatively small numbers of clinical studies, it appears that the hPRL-R levels are elevated in a majority of primary breast cancers [1] [2] [3] . The high levels of hPRL-R in the malignant breast tissue provide an opportunity to design targeted therapeutics such as ligand directed toxin in this case. We show that G129R-PE 40 -KDEL binds to the hPRL-R with 28-fold reduced affinity compared to that of hPRL and retains one tenth of the ability of G129R to inhibit hPRL-induced STAT5 phosphorylation yet drastically increases the specific cytotoxicity. The clinical potential of this ligand targeted toxin will largely depend upon improving the binding affinity of the fusion toxin towards the hPRL-R.
